<font color="blue">Insulin_4</font> <font color="blue">pump_4</font> <font color="blue">therapy_4</font> started at the time of diagnosis : effects on glycemic control and pancreatic β-cell function in type 1 diabetes . 
<br>
<br> BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with type 1 diabetes ( T1D ) , we compared the efficacy of starting <font color="blue">insulin_3</font> <font color="blue">pump_3</font> <font color="blue">therapy_3</font> <font color="blue">at_1</font> <font color="blue">diagnosis_1</font> <font color="blue">with_1</font> <font color="blue">standard_1</font> <font color="blue">multiple_3</font> <font color="blue">daily_3</font> <font color="blue">insulin_3</font> <font color="blue">injections_3</font> <font color="blue">(_3</font> <font color="blue">MDIs_3</font> <font color="blue">)_3</font> <font color="blue">._3</font> 
<br> METHODS We conducted a prospective , randomized , pilot trial <font color="blue">comparing_1</font> <font color="blue">MDI_3</font> <font color="blue">therapy_3</font> <font color="blue">with_2</font> <font color="blue">continuous_4</font> <font color="blue">subcutaneous_5</font> <font color="blue">insulin_5</font> <font color="blue">therapy_5</font> <font color="blue">(_2</font> <font color="blue">pump_2</font> <font color="blue">therapy_2</font> <font color="blue">)_2</font> in 24 patients , 8 - 18 years old , with newly diagnosed T1D. Subjects were evaluated at enrollment and 1 , 3 , 6 , 9 , and 12 months after initial diagnosis of T1D. Preservation of insulin secretion , measured by mixed - meal - stimulated C - peptide secretion , was compared after 6 and 12 months of treatment . Between - group differences in <font color="blue">glycosylated_1</font> <font color="blue">hemoglobin_1</font> <font color="blue">(_1</font> <font color="blue">HbA1c_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> continuous glucose sensor data , insulin utilization , anthropometric measures , and <font color="blue">patient_1</font> <font color="blue">satisfaction_1</font> <font color="blue">with_1</font> <font color="blue">therapy_2</font> were also compared at multiple time points . 
<br> RESULTS Initiation of <font color="blue">pump_2</font> <font color="blue">therapy_2</font> within 1 month of diagnosis resulted in consistently higher mixed - meal tolerance test - stimulated C - peptide values at all time points , although these differences were not statistically significant . Nonetheless , improved glycemic control was observed in <font color="blue">insulin_2</font> <font color="blue">pump_2</font> <font color="blue">-_2</font> <font color="blue">treated_2</font> <font color="blue">subjects_1</font> ( more time spent with normoglycemia , better mean HbA1c ) , and <font color="blue">pump_2</font> <font color="blue">-_2</font> <font color="blue">treated_2</font> <font color="blue">subjects_1</font> reported comparatively greater satisfaction with route of <font color="blue">treatment_1</font> administration . 
<br> CONCLUSIONS Initiation of <font color="blue">insulin_3</font> <font color="blue">pump_3</font> <font color="blue">therapy_3</font> at diagnosis improved glycemic control , was well tolerated , and contributed to improved patient satisfaction with <font color="blue">treatment_1</font> <font color="blue">._1</font> This study also suggests that earlier use of <font color="blue">pump_2</font> <font color="blue">therapy_2</font> might help to preserve residual β-cell function , although a larger clinical trial would be required to confirm this .